⌘K

Login Start Free

Home/Filings/4/0001628280-25-058506

4//SEC Filing

Mottola Frank 4

Accession 0001628280-25-058506

CIK 0001356576other

View on SEC.gov Company Profile

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 4:04 PM ET

Size

14.5 KB

Accession

0001628280-25-058506

Insider Transaction Report

Form 4

Period: 2025-12-19

SUPERNUS PHARMACEUTICALS, INC.SUPN

SVP, Quality, GMP, Ops, IT

Transactions

Exercise/Conversion
Common Stock
2025-12-19$39.40/sh+5,000$197,000→ 20,496 total
Sale
Common Stock
2025-12-19$50.22/sh−5,000$251,100→ 15,496 total
Exercise/Conversion
Common Stock
2025-12-19$25.30/sh+15,000$379,500→ 30,496 total
Sale
Common Stock
2025-12-19$50.47/sh−15,000$757,050→ 15,496 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-19−5,000→ 0 total
Exercise: $39.40Exp: 2028-02-14→ Common Stock (5,000 underlying)
Exercise/Conversion
Employee Stock Option (Right to Buy)
2025-12-19−15,000→ 0 total
Exercise: $25.30Exp: 2027-02-24→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.39. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.69. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F4]The option vests in four equal annual installments beginning on February 14, 2019 .
[F5]The option vests in four equal annual installments beginning on February 24, 2018.

Documents

1 file

4
wk-form4_1766437463.xmlPrimary
FORM 4

Issuer

SUPERNUS PHARMACEUTICALS, INC.

CIK 0001356576

Entity typeother

Related Parties

1

filerCIK 0001804567

Filing Metadata

Form type: 4
Filed: Dec 21, 7:00 PM ET
Accepted: Dec 22, 4:04 PM ET
Size: 14.5 KB

View on SEC.gov